BACKGROUND:Radiofrequency ablation (RFA) is safe and effective for eradicating neoplasia in Barrett's esophagus. OBJECTIVE: To evaluate RFA for eradicating early esophageal squamous cell neoplasia (ESCN) defined as moderate-grade squamous intraepithelial neoplasia (MGIN) and high-grade squamous intraepithelial neoplasia (HGIN) and early flat-type esophageal squamous cell carcinoma (ESCC). DESIGN: Prospective cohort study. SETTING: Tertiary referral center. PATIENTS: Esophageal unstained lesions (USLs) were identified using Lugol's chromoendoscopy. Inclusion criteria were at least 1 flat (type 0-IIb) USL 3 cm or larger, USL-bearing esophagus 12 cm or less, and a consensus diagnosis of MGIN, HGIN, or ESCC by 2 expert GI pathologists. Exclusion criteria were previous endoscopic resection or ablation, stricture, or any nonflat mucosa. INTERVENTIONS: Circumferential RFA creating a continuous treatment area (TA) including all USLs. At 3-month intervals thereafter, chromoendoscopy with biopsies followed by focal RFA of USLs, if present. MAIN OUTCOME MEASUREMENTS: Complete response (CR) at 12 months defined as absence of MGIN, HGIN, or ESCC in the TA, CR after 1 RFA session, neoplastic progression from baseline, and adverse events. RESULTS:Twenty-nine patients (14 male, mean age 60.3 years) with MGIN (n = 18), HGIN (n = 10), or ESCC (n = 1) participated. Mean USL length was 6.2 cm (TA 8.2 cm). At 3 months after 1 RFA session, 86% of patients (25/29) had a CR. At 12 months, 97% of patients (28/29) had a CR. There was no neoplastic progression. There were 4 strictures, all dilated to resolution. LIMITATIONS: Single-center study with limited number of patients. CONCLUSIONS: In patients with early ESCN (MGIN, HGIN, flat-type ESCC), RFA was associated with a high rate of histological complete response (97% of patients), no neoplastic progression, and an acceptable adverse event profile.
RCT Entities:
BACKGROUND: Radiofrequency ablation (RFA) is safe and effective for eradicating neoplasia in Barrett's esophagus. OBJECTIVE: To evaluate RFA for eradicating early esophageal squamous cell neoplasia (ESCN) defined as moderate-grade squamous intraepithelial neoplasia (MGIN) and high-grade squamous intraepithelial neoplasia (HGIN) and early flat-type esophageal squamous cell carcinoma (ESCC). DESIGN: Prospective cohort study. SETTING: Tertiary referral center. PATIENTS: Esophageal unstained lesions (USLs) were identified using Lugol's chromoendoscopy. Inclusion criteria were at least 1 flat (type 0-IIb) USL 3 cm or larger, USL-bearing esophagus 12 cm or less, and a consensus diagnosis of MGIN, HGIN, or ESCC by 2 expert GI pathologists. Exclusion criteria were previous endoscopic resection or ablation, stricture, or any nonflat mucosa. INTERVENTIONS: Circumferential RFA creating a continuous treatment area (TA) including all USLs. At 3-month intervals thereafter, chromoendoscopy with biopsies followed by focal RFA of USLs, if present. MAIN OUTCOME MEASUREMENTS: Complete response (CR) at 12 months defined as absence of MGIN, HGIN, or ESCC in the TA, CR after 1 RFA session, neoplastic progression from baseline, and adverse events. RESULTS: Twenty-nine patients (14 male, mean age 60.3 years) with MGIN (n = 18), HGIN (n = 10), or ESCC (n = 1) participated. Mean USL length was 6.2 cm (TA 8.2 cm). At 3 months after 1 RFA session, 86% of patients (25/29) had a CR. At 12 months, 97% of patients (28/29) had a CR. There was no neoplastic progression. There were 4 strictures, all dilated to resolution. LIMITATIONS: Single-center study with limited number of patients. CONCLUSIONS: In patients with early ESCN (MGIN, HGIN, flat-type ESCC), RFA was associated with a high rate of histological complete response (97% of patients), no neoplastic progression, and an acceptable adverse event profile.
Authors: Farin Kamangar; Paul T Strickland; Akram Pourshams; Reza Malekzadeh; Paolo Boffetta; Mark J Roth; Christian C Abnet; Mitra Saadatian-Elahi; Nasser Rakhshani; Paul Brennan; Arash Etemadi; Sanford M Dawsey Journal: Anticancer Res Date: 2005 Jan-Feb Impact factor: 2.480
Authors: G-Q Wang; C C Abnet; Q Shen; K J Lewin; X-D Sun; M J Roth; Y-L Qiao; S D Mark; Z-W Dong; P R Taylor; S M Dawsey Journal: Gut Date: 2005-02 Impact factor: 23.059
Authors: Virender K Sharma; H Jae Kim; Ananya Das; Christopher D Wells; Cuong C Nguyen; David E Fleischer Journal: Am J Gastroenterol Date: 2009-01-27 Impact factor: 10.864
Authors: Gina D Tran; Xiu-Di Sun; Christian C Abnet; Jin-Hu Fan; Sanford M Dawsey; Zhi-Wei Dong; Steven D Mark; You-Lin Qiao; Philip R Taylor Journal: Int J Cancer Date: 2005-01-20 Impact factor: 7.396
Authors: Nicholas J Shaheen; Prateek Sharma; Bergein F Overholt; Herbert C Wolfsen; Richard E Sampliner; Kenneth K Wang; Joseph A Galanko; Mary P Bronner; John R Goldblum; Ana E Bennett; Blair A Jobe; Glenn M Eisen; M Brian Fennerty; John G Hunter; David E Fleischer; Virender K Sharma; Robert H Hawes; Brenda J Hoffman; Richard I Rothstein; Stuart R Gordon; Hiroshi Mashimo; Kenneth J Chang; V Raman Muthusamy; Steven A Edmundowicz; Stuart J Spechler; Ali A Siddiqui; Rhonda F Souza; Anthony Infantolino; Gary W Falk; Michael B Kimmey; Ryan D Madanick; Amitabh Chak; Charles J Lightdale Journal: N Engl J Med Date: 2009-05-28 Impact factor: 91.245
Authors: Aymeric Becq; Marine Camus; Gabriel Rahmi; Vincent de Parades; Philippe Marteau; Xavier Dray Journal: United European Gastroenterol J Date: 2015-08 Impact factor: 4.623
Authors: Marnix Jansen; Dirk W Schölvinck; Ryoji Kushima; Shigeki Sekine; Bas L A M Weusten; Guiqi Q Wang; David E Fleischer; Shigetaka Yoshinaga; Sanford M Dawsey; Sybren L Meijer; Jacques J G H M Bergman; Ichiro Oda Journal: Gastrointest Endosc Date: 2014-12 Impact factor: 9.427
Authors: Yan Ke; Sanne N van Munster; Liyan Xue; Shun He; Yueming Zhang; Lizhou Dou; Yong Liu; Xudong Liu; Yumeng Liu; Wei Li; Ning Lv; Sanford M Dawsey; Bas L A M Weusten; Jacques J G H M Bergman; Guiqi Wang Journal: Gastrointest Endosc Date: 2019-03-25 Impact factor: 9.427